REYE SYNDROME REVISED WARNING OPPOSED BY P&G, ASPIRIN FOUNDATION
This article was originally published in The Tan Sheet
Executive Summary
REYE SYNDROME REVISED WARNING OPPOSED BY P&G, ASPIRIN FOUNDATION of America in comments on FDA's Oct. 20 proposal to revise the Reye syndrome warning on aspirin and to require the warning on both aspirin and non-aspirin salicylate products. The two commenters objected to the proposal, in part, on the grounds that the revised warning, which is based on the voluntary warning used for Procter & Gamble's bismuth subsalicylate product, Pepto- Bismol, does not take into consideration the different conditions for which aspirin and other salicylate products are used.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning